205 related articles for article (PubMed ID: 31357193)
1. A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms.
Al-Toubah T; Schell MJ; Cives M; Zhou JM; Soares HP; Strosberg JR
Neuroendocrinology; 2020; 110(5):377-383. PubMed ID: 31357193
[TBL] [Abstract][Full Text] [Related]
2. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
Capdevila J; Fazio N; Lopez C; Teulé A; Valle JW; Tafuto S; Custodio A; Reed N; Raderer M; Grande E; Garcia-Carbonero R; Jimenez-Fonseca P; Hernando J; Bongiovanni A; Spada F; Alonso V; Antonuzzo L; Spallanzani A; Berruti A; La Casta A; Sevilla I; Kump P; Giuffrida D; Merino X; Trejo L; Gajate P; Matos I; Lamarca A; Ibrahim T
J Clin Oncol; 2021 Jul; 39(20):2304-2312. PubMed ID: 33945297
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
[TBL] [Abstract][Full Text] [Related]
8. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Castellani F; Visentin A; Campagnolo M; Salvalaggio A; Cacciavillani M; Candiotto C; Bertorelle R; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32284437
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
10. Inhibition of effector B cells by ibrutinib in systemic sclerosis.
Einhaus J; Pecher AC; Asteriti E; Schmid H; Secker KA; Duerr-Stoerzer S; Keppeler H; Klein R; Schneidawind C; Henes J; Schneidawind D
Arthritis Res Ther; 2020 Mar; 22(1):66. PubMed ID: 32228672
[TBL] [Abstract][Full Text] [Related]
11. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
12. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
Strosberg JR; Chan JA; Ryan DP; Meyerhardt JA; Fuchs CS; Abrams T; Regan E; Brady R; Weber J; Campos T; Kvols LK; Kulke MH
Endocr Relat Cancer; 2013 Jun; 20(3):383-90. PubMed ID: 23572164
[TBL] [Abstract][Full Text] [Related]
13. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
14. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
[TBL] [Abstract][Full Text] [Related]
15. Management of Ibrutinib Toxicities: a Practical Guide.
Lasica M; Tam CS
Curr Hematol Malig Rep; 2020 Jun; 15(3):177-186. PubMed ID: 32415406
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.
Metzler JM; Burla L; Fink D; Imesch P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32532074
[TBL] [Abstract][Full Text] [Related]
17. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
19. Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair.
Ye Z; Wang Y; Wu H; Song T; Li X; Liu Q; Wang C
Chembiochem; 2021 Jan; 22(1):129-133. PubMed ID: 32979005
[TBL] [Abstract][Full Text] [Related]
20. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
Abdel-Rahman O; Fouad M
Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
